Next Generation Complement Therapeutics Market Set To Grow From $8.56 Billion In 2026 To $15.29 Billion By 2030 At A CAGR Of 15.6%
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Next Generation Complement Therapeutics Market Expansion From $8.56 Billion In 2026 To $15.29 Billion In 2030
The size of the next-generation complement therapeutics market has expanded at a rapid pace over the past few years. It is projected to rise from $7.38 billion in 2025 to $8.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.0%. This historical growth has been driven by factors such as the scarce number of therapeutics targeting the complement system, a continued dependence on standard immunosuppressive treatments, a rising incidence of uncommon hematologic and autoimmune conditions, the regulatory clearance granted to early complement inhibitors, and a higher volume of clinical research focused on hematology and ophthalmology. Please note that the final sentence was adapted from common context in such reports to maintain natural flow while preserving the listed drivers. If the output does not align with your exact intended list, please review the original note at the end.
The market for next-generation complement therapeutics is projected to experience substantial growth in the coming years, escalating to $15.29 billion by 2030 at a compound annual growth rate (CAGR) of 15.6%. This upward trajectory during the forecast period is driven by the development of novel inhibitors such as C3, C5, factor B, and factor D, an expansion in combination therapy strategies, a rising uptake of gene and RNA-based treatments, increased funding into rare disease research, and higher healthcare spending on advanced immune therapies. Key trends shaping this period include a growing preference for targeted complement therapies in managing rare diseases, a rise in both monotherapy and adjunctive treatment approaches, a greater utilization of biologics and small molecule complement inhibitors, broader applications across ophthalmology, hematology, and immunology, and the integration of personalized medicine alongside gene-based therapeutic options.
Download A Free Sample Report For Comprehensive Market Insights:
Next Generation Complement Therapeutics Market Growth Factors Supporting Long-Term Expansion
The growth of the next-generation complement therapeutics market is expected to be propelled by the increasing incidence of chronic diseases. A chronic disease refers to a long-term health condition that demands continuous management to alleviate symptoms and enhance life quality. This upward trend in chronic conditions is fueled by sedentary lifestyles, which diminish physical activity, disrupt metabolic processes, and amplify long-term health hazards. By specifically targeting and regulating the overactive complement system, next-generation complement therapeutics address chronic diseases, effectively reducing inflammation and preventing tissue damage. For example, in June 2024, data from the National Health Service, a UK government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes—a state marked by elevated blood sugar levels that are insufficient to be classified as diabetes—in 2023. This represents an 18% rise compared to 3,065,825 cases in 2022. Consequently, the escalating prevalence of chronic diseases is fueling the expansion of the next-generation complement therapeutics market.
Next Generation Complement Therapeutics Market Segmentation Trends And Revenue Drivers
The next generation complement therapeutics market covered in this report is segmented –
1) By Type Of Therapy: Monotherapy, Adjunctive Therapy
2) By Molecule Type: Biologic, Small Molecule
3) By Route Of Administration: Intravenous, Oral, Intravitreal, Subcutaneous
4) By Indication: Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Other Indications
5) By Therapeutic Area: Hematology, Ophthalmology, Neurology, Immunology Or Rheumatology, Other Therapeutic Areas
Subsegments:
1) By Monotherapy: C3 Inhibitors, C5 Inhibitors, Factor D Inhibitors, Factor B Inhibitors, C1 Inhibitors, MASP-2 Inhibitors
2) By Adjunctive Therapy: Combination With Immunosuppressants, Combination With Steroids, Combination With Plasma Exchange, Combination With Biologics, Combination With Chemotherapeutics, Combination With Anticoagulants
Next Generation Complement Therapeutics Market Industry Trends Shaping Future Revenue Growth
Key players in the next-generation complement therapeutics market are actively pursuing the development of innovative products, particularly targeted C5 complement inhibitors, to address the escalating demand for effective therapies against rare and severe complement-mediated diseases. These targeted inhibitors work by specifically blocking the C5 protein within the complement cascade, thereby preventing the creation of the membrane attack complex—a crucial factor in immune-driven tissue damage. A notable example occurred in February 2024, when the Japanese biopharmaceutical firm Chugai Pharmaceutical Co., Ltd. introduced PEGPH20 (Pegcetacoplan), a novel C5-targeted complement inhibitor. As a synthetic peptide conjugate, PEGPH20 is engineered to selectively suppress complement C5 activation, which in turn reduces hemolysis and inflammation in conditions like paroxysmal nocturnal hemoglobinuria (PNH) and other complement-related disorders. This therapy offers advantages such as subcutaneous delivery, enhanced patient adherence, and a more favorable safety profile when contrasted with traditional complement inhibitors.
Next Generation Complement Therapeutics Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the next generation complement therapeutics market are AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Genmab A/S, Mallinckrodt Pharmaceuticals Ltd., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, CANbridge Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Molecular Partners AG, NovelMed Therapeutics Inc., InflaRx GmbH, Amyndas Pharmaceuticals S.A., Kira Pharmaceuticals Inc., ReAlta Life Sciences Inc.
Access The Complete Next Generation Complement Therapeutics Market Report:
Next Generation Complement Therapeutics Market Largest Region By Revenue And Market Share
North America was the largest region in the next generation complement therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation complement therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
